X-Feed Billboard (International)

The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.

GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.

System-State: Number of processed items 55.878 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
GlobeNewsWire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
AU000000CUV3
State: 10.03.2025 | 9AM
Do you already know our new terminal view? Click here.
FIGI: BBG000C0XHQ3
CUV

Clinuvel Pharmaceuticals Limited
GICS: - · Sector: Pharmaceuticals, Biotechnology & Life Sciences · Sub-Sector: -
NAME
Clinuvel Pharmaceuticals Limited
ISIN
AU000000CUV3
TICKER
CUV
MIC
XASX
REUTERS
CUV.AX
BLOOMBERG
CUV AU
Tue, 04.03.2025       Clinuvel Pharmaceuticals

MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, with an immersive exhibition that illuminates the past, present and future of photomedicine.

Clinuvel Pharmaceuticals
Mon, 30.09.2024       Clinuvel Pharmaceuticals

CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).
Clinuvel Pharmaceuticals
Tue, 18.06.2024       Clinuvel Pharmaceuticals

CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
Clinuvel Pharmaceuticals

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.